Related Experiment Video

Updated: Mar 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

[Pharmaco-invasive Approach Aimed at Preserved Left Ventricular Function in Patients With Stable Coronary Heart

E O Vershinina1, T R Ryabova1, A N Repin1

  • 1Research Institute for Cardiology, Tomsk, Russia.

Kardiologiia
|March 16, 2017
PubMed

Insights

Trimetazidine, a myocardial cytoprotector, significantly improved left ventricular function in coronary artery disease patients post-stenting. This cardiac medication enhanced contractile function 12 months after revascularization.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Context:

  • Stable coronary artery disease (CAD) patients with carbohydrate metabolism disorders often undergo percutaneous coronary intervention (PCI).
  • Optimizing myocardial function post-PCI is crucial for long-term outcomes.
  • Standard therapy may not fully address metabolic disturbances impacting cardiac function.

Purpose:

  • To evaluate the efficacy of trimetazidine as an adjunct to standard therapy in patients with stable CAD undergoing elective coronary stenting.
  • To assess the impact of trimetazidine on left ventricular contractile function post-PCI.

Summary:

  • A prospective, randomized controlled trial involved 63 stable CAD patients with carbohydrate metabolism disorders undergoing coronary stenting.
  • The main group (n=32) received trimetazidine (35 mg BID) for 2 weeks pre-intervention, while the control group (n=31) received standard therapy.
  • Trimetazidine significantly improved left ventricular ejection fraction (LVEF) by 2.5%, reduced end-diastolic index by 5.5%, and end-systolic index by 4.4% at 12 months post-PCI.

Impact:

  • Long-term administration of trimetazidine enhances myocardial contractile function in CAD patients after coronary stenting.
  • Trimetazidine offers a potential therapeutic benefit for cardiac metabolism and function in patients with metabolic disorders.
  • Findings support trimetazidine's role in improving cardiac performance following revascularization procedures.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.7K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.4K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
786
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441